There was less development or progression of encephalopathy ( 28.6 vs. 60.0 % , P = 0.008 ) and hepatorenal syndrome ( 31.4 vs. 54.3 % , P = 0.05 ) , and the response to treatment ( Lille model ) was higher in the metadoxine group ( 0.38 vs. 0.63 , P = 0.001 ; 95 % CI 0.11 to 0.40 ) .